Levonorgestrel 52 mg intrauterine system (Levosert®)/Liletta®) in contraception: a profile of its use
Funding The preparation of this review was not supported by any external funding.
Authorship and conflicts of interest K.A. Lyseng-Williamson is a salaried employee of Adis International Limited/Springer Nature and an editor of Drugs & Therapy Perspectives. She was not involved in any publishing decisions for this manuscript and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here
Levosert® (EU)/Liletta® (USA) is a levonorgestrel (LNG)-releasing intrauterine system (IUS) containing 52 mg of LNG. It was the first LNG-releasing IUS approved for use for up to 6 years, with daily LNG release rates being sufficient to provide contraception over at least this time period. In the efficacy population (1600 women aged 16–35 years) of the key ongoing 10-year ACCESS IUS trial, Levosert/Liletta 52 mg was highly effective in preventing pregnancy and improving bleeding patterns. Levosert/Liletta 52 mg also reduces heavy menstrual bleeding (HMB), with no differences in improvements in HMB outcomes between Levosert/Liletta 52 mg and Mirena® 52 mg in a 1-year trial, and no reports of HMB by the end of cycle 2 in 75% of 150 women with self-reported baseline HMB in ACCESS IUS. In the ACCESS IUS safety population (1751 women aged 16–45 years), the tolerability of Levosert/Liletta 52 mg was consistent with the known profile of LNG-releasing IUSs, with few treatment-related serious adverse events or complications. IUSs releasing LNG 52 mg offer the convenience of less frequent insertion than IUSs releasing LNG 13.5 or 19.5 mg, and may be of particular value in women with HMB wanting long-acting reversible contraception.
© Springer Nature Switzerland AG 2020